Please login to the form below

Not currently logged in
Email:
Password:

Bayer UK and Ireland appoints new CEO

Lars Bruening succeeds Alex Moscho

Lars BrueningBayer has appointed a new UK and Ireland CEO in the form of Lars Bruening, who moves to its Reading, UK base from Berlin where he was head of the pharma group’s global market access business.

Prior to that Bruening held senior commercial roles in Europe, the Middle East and Asia, bringing knowledge in the pharmaceutical sector, international healthcare landscape and global commercial markets to the group.

He said: “Looking in from afar, the progress the UK and Ireland has made over the last four years alone, with the UK becoming the third largest Bayer market in Europe and the eighth largest in the world, as well as the progress made in individual markets also reflects the ongoing work with our partners and colleagues at the grassroots levels.

“It is this, which I am incredibly proud of and look forward to building upon this existing success.”

Bruening succeeds Alexander Moscho, who left Bayer after seven years to join UCB as its chief strategy officer.

16th October 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

The ALS patient journey
Nick Goldup is the Director of Care Improvement at the Motor Neuron Disease Association (MNDA). Here, he offers his insights into the journey for patients with ALS and explores the...
Equipping your medical affairs teams with solutions to navigate the healthcare landscape
Dr Tyler Ray, OPEN Health Medical Communications...
Protein degraders
Can protein degraders unlock ‘undruggable’ drug targets?
Exploring a new and exciting area of small-molecule drug discovery...

Infographics